The cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors are likely to override the risk of harm in many patients with type 2 diabetes, a new study has found. However the large systematic review and meta-analysis published online in The Lancet Diabetes & Endocrinology, highlighted significant side effects including increased genital infections, and called for some ...
Type 2 diabetes
Cardiovascular benefits of SGLT2 inhibitors may override risk of harm
By Amanda Sheppeard
24 Mar 2016